Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 3
2010 4
2011 1
2012 7
2013 4
2014 3
2015 1
2016 2
2017 1
2018 4
2019 5
2020 5
2021 6
2022 10
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
Amin NB, Darekar A, Anstee QM, Wong VW, Tacke F, Vourvahis M, Lee DS, Charlton M, Alkhouri N, Nakajima A, Yunis C. Amin NB, et al. Among authors: vourvahis m. BMJ Open. 2022 Mar 30;12(3):e056159. doi: 10.1136/bmjopen-2021-056159. BMJ Open. 2022. PMID: 35354614 Free PMC article. Clinical Trial.
Pharmacokinetics and safety of maraviroc in neonates.
Rosebush JC, Best BM, Chadwick EG, Butler K, Moye J, Smith E, Bradford S, Reding CA, Mathiba SR, Hanley S, Aziz M, Homans J, Acosta EP, Murtaugh W, Vourvahis M, Mcfadyen L, Hayward K, Mirochnick M, Samson P; IMPAACT 2007 Study Team. Rosebush JC, et al. Among authors: vourvahis m. AIDS. 2021 Mar 1;35(3):419-427. doi: 10.1097/QAD.0000000000002762. AIDS. 2021. PMID: 33252481 Free PMC article.
Towards a Maraviroc long-acting injectable nanoformulation.
Tatham LM, Savage AC, Dwyer A, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A. Tatham LM, et al. Among authors: vourvahis m. Eur J Pharm Biopharm. 2019 May;138:92-98. doi: 10.1016/j.ejpb.2018.04.009. Epub 2018 Apr 21. Eur J Pharm Biopharm. 2019. PMID: 29684534
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
Liyanage M, Nikanjam M, McFadyen L, Vourvahis M, Rogg L, Moye J, Chadwick EG, Jean-Philippe P, Mirochnick M, Whitson K, Bradford S, Capparelli EV, Best BM. Liyanage M, et al. Among authors: vourvahis m. Pediatr Infect Dis J. 2022 Nov 1;41(11):885-890. doi: 10.1097/INF.0000000000003665. Epub 2022 Aug 9. Pediatr Infect Dis J. 2022. PMID: 35980827
52 results